In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.
Chemotherapy Utilized in Pretreated Metastatic Castration-Resistant Prostate Cancer
In the first article of a 2-part series, Mehmet A. Blien, MD, discusses where cabazitaxel fits into the treatment paradigm for patients with metastatic castration resistant prostate cancer.
In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.
In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
During a live virtual event, Edwin M. Posadas, MD, discussed the use of cabazitaxel in patients with metastatic castration-resistant prostate cancer with participants. This is the second of 2 articles based on this event.
During a live virtual event, Edwin M. Posadas, MD, discussed patient factors for choosing the type of therapy to use after progression on androgen receptor therapy and chemotherapy with participants.
During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.